Abstract: Methods for determining an analyte in a sample by immunoassay in a one-step format without performing washing steps are described. The method includes a first analyte-specific receptor that contains at least two binding sites for the analyte, and a second analyte-specific receptor that selectively binds to an aggregate arrangement of at least two analyte molecules bound to the first receptor.

Abstract: The invention relates to a method for determining an analyte in a sample by means of an assay that can be carried out in a one-step format without performing washing steps. The method includes a first analyte-specific receptor that contains at least one bonding point for the analyte, e.g., several antibodies on a particle, as well as a second analyte-specific receptor that can selectively bond to an arrangement comprising at least two analyte molecules which are bound to the first receptor. An antibody sandwich immune assay is described in which the detection is based on electrochemiluminescence.

Abstract: The invention relates to a process for the production of a biomolecule-linker conjugate of uniform stochiometry. It especially relates to a conjugate consisting of a biomolecule of a molecular weight between 5 kD and 500 kD and a hydrophilic linker molecule said linker having a molecular weight between 1 and 15 kD and between 4 and 60 charged residues, characterized in that said conjugate comprises at least one biomolecule-linker product of uniform stoichiometry in a pre-selected amount.

Abstract: The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase.

Abstract: The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase.

Abstract: The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase.

Abstract: The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase.

Abstract: The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase.

Abstract: The present invention relates to determining the prethrombotic state, in particular determining an amount or presence of circulating microparticles and/or stimulated procoagulant cells.

Abstract: The present invention concerns a method for producing microparticles loaded with proteins which is characterized in that the microparticles are loaded in suspension under strongly alkaline conditions. The invention also concerns microparticles which can be produced using this method and their use in a binding test e.g. in an immunoassay.

Abstract: The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase.

Abstract: The invention relates to a process for the production of a biomolecule-linker conjugate of uniform stochiometry. It especially relates to a conjugate consisting of a biomolecule of a molecular weight between 5 kD and 500 kD and a hydrophilic linker molecule said linker having a molecular weight between 5 kD 15 kD and between 4 and 60 charged residues, characterized in that said conjugate comprises at least one biomolecule-linker product of uniform stoichiometry in a pre-selected amount.

Abstract: The invention concerns a process for diagnosis of an HIV infection by means of an immunoassay using the specific detection of the p24 antigen of HIV1, HIV1-Sub0 and/or the p26 antigen of HIV2, at least one antibody against the env region of HIV1, HIV1-Sub0 and/or of HIV2 and at least one antibody against the pol and/or gag region of HIV1, HIV1-Sub0 and/or HIV2, reagent kits and test strips suitable for diagnostic procedure as well as monoclonal antibodies against p24 and their use.

Abstract: The invention concerns a method f or the determination of an analyte in which rheumatoid factors or rheumatoid-factor-like substances are added as an interference reducing reagent to reduce or avoid a hook effect The invention in addition concerns suitable reagent kits for carrying out the method.

Abstract: The invention concerns a process of the detection of HIV antibodies against HIV by means of an immunoassay wherein at least one antigen of the env gene product gp41 of an HIV1-subtype-D isolate and at least one antigen derived from gp41 of a different HIV1-subtype of the M group is used and/or at least one antigen of gp41 of an HIV1-subtype-E isolate and at least one antigen derived from gp41 of a different HIV1-subtype isolate of the M group. The invention additionally concerns antigens and antigen mixtures with components derived from gp41 of the HIV1-subtype-D isolate and from gp41 of the HIV1-subtype-E isolate, respectively, as well as their use for the detection of HIV antibodies and a reagent kit.

Abstract: The invention concerns a method for the determination of an analyte in which rheumatoid factors or rheumatoid-factor-like substances are added as an interference reducing reagent to reduce of avoid a hook effect. The invention in addition concerns suitable reagent kits for carrying out the method.

Abstract: The invention addresses new photo-activatable biotin derivatives having the formula I ##STR1## wherein R=?(CH.sub.2).sub.n --O.sub.m !.sub.q --?(CH.sub.2).sub.r --O.sub.s !.sub.t --(CH.sub.2).sub.pwith n,r=2,3; m,s=0,1; q+t=1-4; p=1-4,wherein the sum of all CH.sub.2 groups does not exceed 10and wherein R1 as a single or multiple substituent is hydrogen, C.sub.1 -C.sub.5 alkyl, NH.sub.2, COOH, F, Cl, or Br.and their preparation, their use to inactivate streptavidin, the use of the inactivated streptavidin to reduce interference in immunoassays.

Abstract: The invention concerns interference-eliminating agents for avoiding unspecific interactions in immunoassays in which avidin or streptavidin or a derivative thereof are used as the interference-eliminating agents.